Skip to content
StockMarketAgent
Direct answer
argenx is a premier hyper-growth biotech firm transitioning to a commercial powerhouse. Its lead asset, VYVGART, is rapidly becoming the standard of care in generalized Myasthenia Gravis (gMG) and is successfully expanding into CIDP. The 'pipeline-in-a-product' strategy provides a long-duration growth profile with multiple multi-billion dollar indication opportunities. Fair value range: low $654, high $2709, with mid-point at $1486.
Stock analysis

ARGX fair value $654–$2,709

By StockMarketAgent.AI team· supervised by
Geanalyseerd: 2026-05-20Volgende update: 2026-08-20Methodology v2.4Data cut-off: Quality gate: passSources: all material sources passed deterministic freshness/provenance gatesReview: automatedArchetype: Hyper-growth
View archive
Koers
$797.77
▲ +688.71 (+86.33%)
Fair value
$1486
$654–$2709
Beoordeling
Sterk kopen
confidence 82/100
Opwaarts potentieel
+86.3%
upside to fair value
Veiligheidsmarge
$1263.51
MoS level · 15%
Marktkapitalisatie
$49.9B
P/E fwd 21.8
Engelse bronNL
Engelse bron wordt weergegeven terwijl we vertalen
Dit rapport is nog niet vertaald. Vernieuw over een paar minuten zodra de vertaalwachtrij is bijgewerkt.

§1 Samenvatting

  • Commercial-stage status with visible traction in gMG/CIDP provides a reliable valuation floor.
  • Robust pipeline diversity reduces binary outcome risk compared to single-asset biotechs.
  • Forward earnings captures the massive earnings reset expected as assets reach peak penetration.
Fair value
$1,486
Margin of safety
+46.3%
Confidence
82/100
Moat
6.5/10

Educational analysis only — not financial advice. Always do your own due diligence.

$797.77Price
Low $654.18
Mid $1,486.48
High $2,709.48

argenx is a premier hyper-growth biotech firm transitioning to a commercial powerhouse. Its lead asset, VYVGART, is rapidly becoming the standard of care in generalized Myasthenia Gravis (gMG) and is successfully expanding into CIDP. The 'pipeline-in-a-product' strategy provides a long-duration growth profile with multiple multi-billion dollar indication opportunities.

  • IP-protected antibody platform
    IP-protected antibody platform
  • Pipeline-in-a-product strategy
    Pipeline-in-a-product strategy
  • Cycle upside
    High demand for specialized autoimmune therapeutic platforms.

§2 Berenscenario

In a sustained high-cost environment where CIDP expansion falters, valuation relies entirely on established gMG revenues.

Hoe deze these kan breken

FcRn Class Competition

· Medium

Next-generation competitors outcompete on pricing or efficacy, eroding market share.

FV impact
Severe

Secondary Indication Failures

· Low

Regulatory delays or clinical failures across 3+ secondary indications cap revenue.

FV impact
Moderate

Margin Compression

· Medium

Failure to cross 15% operating margins by FY2027 due to sustained high SG&A.

FV impact
Moderate
Vroege waarschuwingssignalen om te volgen
MetriekHuidigTrigger-drempel
Operating margins failing to cross 15% by FY2027.MonitorDeterioration versus the report thesis
Regulatory rejection in secondary indications.MonitorDeterioration versus the report thesis
Clinical failure across more than 3 secondary indications.MonitorDeterioration versus the report thesis
Loss of market share in gMG to competitors.MonitorDeterioration versus the report thesis
Sustained increase in SG&A without revenue growth.MonitorDeterioration versus the report thesis

§3 Financiële historie

Winst-en-verliesrekening — laatste zes perioden
PostT−0T−1T−2T−3CAGR
Periode2022-12-312023-12-312024-12-312025-12-31Trend
Omzet$410.7M$1.23B$2.19B$4.15B+116.2%
Brutowinst$381.3M$1.11B$1.96B$3.70B+113.3%
Bedrijfsresultaat$-723.9M$-420.6M$-17.8M$1.05B—
Nettowinst$-709.6M$-295.1M$833.0M$1.29B—
WPA (verwaterd)$-13.05$-5.16$12.78$19.57—
EBITDA$-622.8M$-192.3M$105.2M$1.31B—
R&D$663.4M$859.5M$983.4M$1.36B+27.2%
VAA$469.9M$709.5M$1.05B$1.36B+42.5%

Kwaliteitsscores

OCF / Nettowinst
0.53×
>1 wijst op hoge winstkwaliteit
Drempel boekhoudkwaliteit
Fail
Sector-aangepaste drempel
ROIC
13.8%
Rendement op geïnvesteerd kapitaal
Sectie 3

Numbers analysis

Kasstroom

Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.

Kapitaalallocatie

Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.

Individuele abonnees — vanaf §411 extra secties

Lees de volledige analyse — 11 extra secties.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

Volledig rapport voor elke gedekte ticker
24 maanden rating-archief
Watchlist-briefings + rating-wijzigingsmeldingen
PDF + DOCX-export in elke taal
Start gratis proefperiode
Op elk moment opzegbaar.
FAQ

ARGX — frequently asked questions

  1. Based on our latest analysis, ARGX looks meaningfully undervalued. The current price is $798 versus a composite fair-value midpoint of $1486 (range $654–$2709), which implies roughly 86.3% upside to the midpoint.

Related coverage

Names readers of ARGX also follow

Same archetype: hyper-growth